Glaxosmithkline

This large, late-stage study is testing whether a new drug called bepirovirsen can provide a functional cure for chronic Hepatitis B. It involves 857 people who are already taking standard antiviral medication. The goal is to see if adding bepirovirsen for 24 weeks can suppress t…

This study is testing whether a single immunotherapy drug, dostarlimab, can effectively treat a specific type of rectal cancer without needing chemotherapy, radiation, or surgery. It involves 154 adults with untreated, locally advanced rectal cancer that has a specific genetic ma…

This large Phase 3 study is testing whether an investigational drug called bepirovirsen can provide a 'functional cure' for people with chronic Hepatitis B. It involves nearly 1,000 participants who are already on standard antiviral medication. The main goal is to see if adding b…

This early-stage study is testing a new pneumonia vaccine called Pn-MAPS30plus in 127 healthy adults aged 50-64. The vaccine aims to protect against more strains of pneumonia bacteria than current vaccines. Researchers will check if the vaccine is safe and if it triggers a good i…

This study aims to find the best time for older adults to get a booster dose of the RSV vaccine after their first shot. It will follow over 10,000 participants for about five years to see how long the vaccine's protection lasts and monitor its safety. The study also offers the re…

This is the first time this new mRNA vaccine for Respiratory Syncytial Virus (RSV) is being tested in people. The study aims to check if different doses are safe and if they trigger a good immune response in 213 healthy adults aged 18-45. Researchers will closely monitor for side…

This study is testing a booster dose of the meningitis B vaccine in healthy people aged 10 to 20 who received the same vaccine as infants. The goal is to see if the booster shot safely strengthens their immune defense against this serious infection. Researchers will compare the i…

This study is testing an investigational vaccine designed to protect adults aged 60 and older from Respiratory Syncytial Virus (RSV) infections. Researchers are checking how safe the vaccine is, how well it triggers an immune response, and how long that protection might last—up t…

This study is testing new flu vaccines made with mRNA technology, similar to some COVID-19 shots. It aims to see how well they trigger an immune response and how safe they are in healthy adults aged 18 and older. The trial is comparing different versions of the vaccine to gather …

This study is testing whether a new long-acting injectable drug called depemokimab works as well as an existing drug called mepolizumab for adults with relapsing or hard-to-treat EGPA, a rare autoimmune disease. Both drugs are given as injections alongside standard steroid medica…

This early-stage study aimed to understand how a drug for relapsed multiple myeloma is processed by the body in people with different levels of liver function. It planned to compare participants with normal liver function to those with impaired function. The study was withdrawn b…

This is the first-ever study in humans of an experimental drug called remzistotug for people with advanced solid tumors. It aims to find a safe dose and see how the body handles the drug, both alone and when combined with other cancer treatments. The trial is for patients with sp…

This study is testing whether a drug called dostarlimab can control a specific type of rectal cancer without needing surgery or radiation first. It is for Chinese patients with untreated, locally advanced cancer that has certain genetic markers. The main goal is to see if the dru…

This is the first study in people to test a new cancer drug called GSK6097608. It aims to find a safe dose and see how the body handles the drug when given alone or combined with other cancer treatments. The study includes about 107 adults with advanced solid tumors that have not…

This early-stage study is testing a new oral drug, GSK4418959, for adults with advanced solid tumors that have specific genetic features (called dMMR or MSI-H). The main goals are to find a safe dose, see how the body processes the drug, and check if it can shrink tumors, either …

This study is testing whether a new drug called belantamab mafodotin works better than the current standard treatment for people with multiple myeloma that has come back or stopped responding to other therapies. About 325 participants will be randomly assigned to receive either t…

This study is testing new combinations of immunotherapy drugs for people with advanced head and neck cancer that has returned or spread. It aims to see if these new combinations work better and are as safe as a single existing immunotherapy drug. The trial will enroll about 316 a…

This large, late-stage trial is comparing a new two-drug combination (belrestotug + dostarlimab) against the current standard treatment (pembrolizumab) for people with advanced non-small cell lung cancer who have not had prior treatment. The main goals are to see if the new combi…

This early-stage study is testing the safety and finding the right dose of a four-drug combination for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The goal is to see if combining these medications can better control th…

This study is testing new combinations of immunotherapy drugs for people with advanced non-small cell lung cancer who haven't had any prior treatment. It focuses on patients whose tumors have high levels of a protein called PD-L1. The main goal is to see how safe these drug combi…

This early-stage study is testing a new oral drug called GSK4524101, both by itself and combined with an existing cancer drug (niraparib), in adults with advanced solid tumors. The main goals are to find safe dose levels and see if the treatment can shrink tumors. It is for peopl…

This early-stage study is testing the safety and best dose of a two-drug combination for people with multiple myeloma that has returned or stopped responding to prior treatments. The trial combines an antibody-drug therapy with an immunotherapy drug. It aims to see if this combin…

This study is testing a new combination of two drugs, cobolimab and dostarlimab, for children and young adults with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest and most effective dose and to see how well the body tolera…

This study aims to see if a three-drug combination inhaler works better than the standard two-drug inhaler for adults whose asthma is not well controlled. It will involve about 1,366 participants and will measure improvements in lung function and asthma symptoms over one year. Th…

This study is testing different dosing schedules for the drug belantamab mafodotin in patients with advanced multiple myeloma that has returned or stopped responding to other treatments. The main goal is to see if changing the dose or timing can reduce serious eye-related side ef…

This study is testing a new long-lasting injection called GSK5784283 for adults whose asthma remains poorly controlled despite using standard daily inhaler medications. The drug works by blocking a specific protein in the body (TSLP) thought to drive asthma inflammation. Research…

This study is testing whether an investigational drug called GSK4532990 can reduce liver scarring and inflammation in adults with advanced NASH, a serious form of fatty liver disease. About 284 participants with confirmed liver damage will receive either the drug or a placebo for…

This study is testing a version of an existing lupus drug, belimumab, given as a shot under the skin (subcutaneous) in children aged 5 to 17. The main goals are to see if the drug reaches safe and effective levels in children's bodies and to monitor for side effects. Participants…

This is a first-in-human study to test the safety and find the right dose of a new drug called GSK3745417. It is being tested alone and in combination with another cancer drug, dostarlimab, in adults with advanced solid tumors that have stopped responding to standard treatments. …

This early-stage study is testing the safety and best dosing schedule of a new drug called belantamab mafodotin when added to standard chemotherapy for adults newly diagnosed with multiple myeloma. The trial is specifically for patients who are not candidates for intensive stem c…

This study is testing a combination of two drugs, belantamab mafodotin and isatuximab, for people with multiple myeloma that has come back or stopped responding to other treatments. The main goals are to find a safe dose for the combination and to see how well it works at control…

This study is testing whether an experimental drug called bepirovirsen can help people who have both HIV and chronic hepatitis B. Researchers want to see if the treatment can clear detectable hepatitis B virus from the blood while participants continue their regular HIV medicatio…

This study is for people with advanced non-small cell lung cancer that has worsened despite standard immunotherapy and chemotherapy. It compares three treatment approaches to see which helps patients live longer: standard chemotherapy alone, chemotherapy plus one immunotherapy dr…

This study is testing whether an investigational intravenous drug called GSK4527226 can slow the progression of early Alzheimer's disease. It will involve 367 people with mild cognitive impairment or mild dementia due to Alzheimer's, who will receive either one of two doses of th…

This study is testing whether adding the drug niraparib to standard pembrolizumab maintenance therapy helps people with advanced non-small cell lung cancer live longer without their cancer getting worse. It involves 666 adults whose cancer stabilized or shrank after initial chemo…

This early-stage trial is testing a combination of four different drugs for people with multiple myeloma that has come back or stopped responding to other treatments. The main goals are to find a safe dose and see how well the body tolerates the combination. It will involve a sma…

This study is testing a targeted cancer drug called belantamab mafodotin, both by itself and in combination with several other anti-cancer drugs. It aims to find safe and effective treatment options for adults with multiple myeloma that has returned or stopped responding to prior…

This study aims to evaluate the long-term safety and tolerability of linerixibat, a medication for severe itching caused by primary biliary cholangitis, a chronic liver disease. The trial includes 242 adults who previously participated in linerixibat studies and will continue rec…

This study is checking the safety of the shingles vaccine (HZ/su) for pregnant women who have weakened immune systems. It will follow about 2,800 women to see if getting the vaccine during pregnancy affects their babies' health, focusing on birth defects and other outcomes. The s…

This is the first time a new drug candidate for lupus is being given to people. The main goal is to check if it is safe and how the body processes it in healthy volunteers. The study is currently suspended and is not testing if the drug helps treat lupus symptoms.